secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001104659-26-002706
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicycle Therapeutics outlines 2026 milestones; zelenectide pevedotin dose selection & approval pathway update in Q1
--------------------------------------------------------------------------------

- Dose selection from Phase 2/3 Duravelo-2 trial and approval update for zelenectide pevedotin in mUC expected in Q1 2026
- Additional EphA2 human imaging data for radiopharmaceuticals pipeline planned for first half of 2026
- Initial data from Phase 1/2 Duravelo-3 trial in NECTIN4-amplified breast cancer expected in second half of 2026
- Financial runway expected into 2028 to support execution of clinical and strategic priorities

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465926002706/0001104659-26-002706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465926002706/tm262874d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-002706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer